Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators..

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084.

PMID:
19297566
2.

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fosså SD; Scandinavian Prostate Cancer Group Study 7.; Swedish Association for Urological Oncology 3..

Lancet. 2009 Jan 24;373(9660):301-8. doi: 10.1016/S0140-6736(08)61815-2. Erratum in: Lancet. 2009 Apr 4;373(9670):1174.

PMID:
19091394
3.

Survival from prostate cancer in England and Wales up to 2001.

Rowan S, Rachet B, Alexe DM, Cooper N, Coleman MP.

Br J Cancer. 2008 Sep 23;99 Suppl 1:S75-7. doi: 10.1038/sj.bjc.6604595. No abstract available.

PMID:
18813268
4.

Quality of life and satisfaction with outcome among prostate-cancer survivors.

Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT.

N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.

PMID:
18354103
5.

Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.

Ferrer M, Suárez JF, Guedea F, Fernández P, Macías V, Mariño A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, Craven-Bratle J, Garin O, Aguiló F; Multicentric Spanish Group of Clinically Localized Prostate Cancer..

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):421-32. doi: 10.1016/j.ijrobp.2007.12.024.

PMID:
18325680
6.

Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer.

Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE.

Cancer. 2007 Jun 1;109(11):2239-47.

PMID:
17455209
8.

Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study.

Buron C, Le Vu B, Cosset JM, Pommier P, Peiffert D, Delannes M, Flam T, Guerif S, Salem N, Chauveinc L, Livartowski A.

Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):812-22.

PMID:
17293235
9.

Estimates of the cancer incidence and mortality in Europe in 2006.

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P.

Ann Oncol. 2007 Mar;18(3):581-92.

PMID:
17287242
10.

Overview of brachytherapy resources in Europe: a survey of patterns of care study for brachytherapy in Europe.

Guedea F, Ellison T, Venselaar J, Borras JM, Hoskin P, Poetter R, Heeren G, Nisin R, François G, Mazeron JJ, Limbergen EV, Ventura M, Taillet M, Cottier B.

Radiother Oncol. 2007 Jan;82(1):50-4.

PMID:
17150270
11.

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis.

Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC.

Cancer. 2006 Nov 15;107(10):2392-400.

PMID:
17041884
12.

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).

Mills N, Metcalfe C, Ronsmans C, Davis M, Lane JA, Sterne JA, Peters TJ, Hamdy FC, Neal DE, Donovan JL.

Contemp Clin Trials. 2006 Oct;27(5):413-9.

PMID:
16774847
13.

Geographic and socioeconomic variation in the treatment of prostate cancer.

Krupski TL, Kwan L, Afifi AA, Litwin MS.

J Clin Oncol. 2005 Nov 1;23(31):7881-8.

PMID:
16204005
14.

Origins of socio-economic inequalities in cancer survival: a review.

Woods LM, Rachet B, Coleman MP.

Ann Oncol. 2006 Jan;17(1):5-19. Review.

PMID:
16143594
15.

Radical prostatectomy versus watchful waiting in early prostate cancer.

Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson SO, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlén BJ, Johansson JE; Scandinavian Prostate Cancer Group Study No. 4..

N Engl J Med. 2005 May 12;352(19):1977-84.

PMID:
15888698
16.

Healthy life expectancy by area deprivation: magnitude and trends in England, 1994-1999.

Bajekal M.

Health Stat Q. 2005 Spring;(25):18-27.

PMID:
15804166
17.

Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival.

Hall SE, Holman CD, Wisniewski ZS, Semmens J.

BJU Int. 2005 Jan;95(1):51-8.

PMID:
15638894
18.

Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.

Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, Harlan LC.

J Natl Cancer Inst. 2004 Sep 15;96(18):1358-67.

PMID:
15367568
19.

Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study.

Melia J, Moss S, Johns L; Contributors in the participating laboratories..

BJU Int. 2004 Jul;94(1):51-6.

PMID:
15217430
20.

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.

Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR.

J Clin Oncol. 2004 Jun 1;22(11):2141-9.

PMID:
15169800
Items per page

Supplemental Content

Support Center